Opioid use is a newly recognized risk factor for the development of osteoporosis in opioid-consuming young adults (1). Such patients have been reported to have a higher incidence of hip fractures than controls (1).

Opioid use may result in opioid-induced androgen deficiency (OPIAD) (1,2). Specifically, testosterone synthesis and hypothalamic gonadotrophin releasing hormone are inhibited by opioids (1,3). It is estimated that in the US as many as 5 million men with chronic non-malignant pain have OPIAD (4), which is associated with decreased libido, erectile dysfunction, fatigue, depressed moods, and hot flashes (1). The long-term effects of low testosterone may result in anemia, sarcopenia, and osteoporosis (1,4). Daniell (2) showed that opiate-induced decreases in testosterone levels occasionally approached the castrate range and were associated with weakness and diminished muscle mass, which presumably contributed to an increased fall and fracture risk.
Opioids also interfere with bone formation independently of hormone changes (1,2). There is a decrease in serum osteocalcin levels in patients who use opioids (1). A large concentration of opioid receptors in osteoblasts inhibits the formation of osteocalcin (1,2).

The purpose of this study was to examine the bone mass density of male patients who have been prescribed opioids for pain management. Furthermore, we sought to determine if a correlation of the total testosterone levels of patients using opioids and bone mass density exists, or if bone mass density is compromised independently of the testosterone level.

**METHODS AND MATERIALS**

Eighty-one male patients (20 to 84 years old) who sought treatment from a regional pain management clinic for chronic pain were included in the study. These patients used opioids to control their pain from a few weeks to 20 years. Total testosterone levels were obtained from blood and bone mass density scans were performed on a recently calibrated Hologic QDR-1000 DXA scanner for all the patients.

Hypogonadism was defined as a total serum testosterone level less than 280 ng/dL. World Health Organization (WHO) criteria for osteopenia and osteoporosis were used. A T-score -1 to -2.5 standard deviations below the mean indicates osteopenia, and a T-score below -2.5 standard deviations indicates osteoporosis. These values are based on post-menopausal Caucasian women. Non-Caucasian female and male standard have not been established at this time.

**RESULTS**

The average age of the 81 patients was 45 years. The average duration on opioids was 2.5 years. Thirty-six patients (44%) had bone mass densities in the osteopenic and osteoporotic ranges (Table 1). Twenty-two patients (27%) included in this study were considered hypogonadal (Table 1). Eleven of the patients (50%) that were hypogonadal had bone mass densities in the osteopenic or osteoporotic range (Table 1). More interestingly, 25 men (42%) had a total testosterone level within normal range and were osteopenic or osteoporotic (Table 1).

**DISCUSSION**

We found that 44% of the men involved in this study had bone mass densities in the osteopenic/osteoporotic range, even though only 27% were hypogonadal. Forty-two percent of the patients whose testosterone values were within normal limits also had lowered bone mass densities. Fifty-three percent of the men in the study disclosed that they smoked.

The reference ranges for osteoporosis and osteopenia are based on the WHO criteria of a population of post-menopausal Caucasian women. The reference range for men has not been established at this time. Therefore, the osteopenic/osteoporotic classification of our subjects is approximate but undoubtedly underestimates the percentage in men, because of their higher bone density values.

The production of testosterone decreases naturally as men age (5). The term andropause has been used to describe the phenomena of approximately 1% decrease of testosterone per year decline after the age of 30 in men (5). It is also believed that hypogonadism is better determined by the symptoms than by a specific serum level because testosterone levels causing dysfunction vary widely among individuals (5). Hypogonadal symptoms may be present in patients who have a total testosterone level within normal limits. Therefore, even the patients who have normal-appearing testosterone levels may exhibit the effects of hypogonadism, including decreased bone mass density.

Additional factors may also contribute to a decrease in bone mass density. Lifestyle choices such as smoking, alcohol intake, drugs, and other existing

---

**Table 1. Bone Density Results**

<table>
<thead>
<tr>
<th>Testosterone Range</th>
<th>Normal</th>
<th>Osteopenic</th>
<th>Osteoporotic</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypogonadal</td>
<td>11 (50%)</td>
<td>9 (41%)</td>
<td>2 (9%)</td>
<td>22 (27%)</td>
</tr>
<tr>
<td>Non-hypogonadal</td>
<td>34 (58%)</td>
<td>20 (34%)</td>
<td>5 (8%)</td>
<td>59 (73%)</td>
</tr>
<tr>
<td>Total</td>
<td>45 (56%)</td>
<td>29 (36%)</td>
<td>7 (8%)</td>
<td>81 (100%)</td>
</tr>
</tbody>
</table>
medical conditions are all risk factors for developing osteoporosis (6). Scartberg et al (7) showed that total and free testosterone levels were positively and significantly associated with tobacco consumption, and that smokers have significantly higher levels of total testosterone. They also showed that men with a high body mass index (BMI) were more likely and smokers less likely to be in the lowest quintile of total testosterone (7). Vermeulen et al (8) showed that in healthy men the BMI accentuated the decline in androgen levels but may be partially masked when data are not corrected for the influence of smoking. Fifty-three percent of the participants in this study smoked. Forty-nine percent of the smokers had bone density values in the osteopenic/osteoporotic ranges. Alcohol consumption, BMI, and activity levels were not evaluated, but could possibly contribute to the reduced bone mass density of our patients.

Opioid use may induce hypogonadism (1,2). The National Institutes of Health in 2002 recommended that physicians pay particular attention to the skeletal health in individuals with certain medical conditions or who are taking certain drugs (9). They included persons with hypogonadism in this group.

This study does have some limitations. The patients in this study were referral patients. As many pain intervention practices are well aware, these patients have already been treated with opioids prior to seeking care from their practices. Therefore, baseline data for the DEXA scan and testosterone levels were unavailable. Other variables historically affecting bone density, such as medication, nutrition, weight bearing activity, etc., may also impact the bone density data.

The total testosterone level may not a reliable screen for determining hypogonadism in men using opioids. Bone density screening is the only definitive and practical means to monitor the bone mass density in these patients. Our findings for the population of this study suggest that further investigations should be undertaken in an effort to help determine whether patients on opioid therapy for one year or more should have a DEXA scan to monitor bone mass density.

**Conclusion**

Routine screening for bone mass density may be an excellent asset in the management of men prescribed opioids for chronic pain, because it may prevent additional health problems associated with osteoporosis.

**References**